Search
ReN001
go.drugbank.com/drugs/DB05236InvestigationalReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. … ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans
Diethylpropion
go.drugbank.com/drugs/DB00937ApprovedIllicitInvestigationalA appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. … It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
International brands: LineaDroloxifene
go.drugbank.com/drugs/DB15641ExperimentalIts higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity … It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required.
Categories: Compounds used in a research, industrial, or household settingEvinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigationalEvinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH. … The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years.
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalRolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. … Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and
Eucalyptol
go.drugbank.com/drugs/DB03852ApprovedInvestigationalNutraceuticalIt kills leukaemia cells in vitro. … Eucalyptol is naturally produced cyclic ether and monoterpenoid. Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant.
Mixtures: Demo Cineol InjCategories: Compounds used in a research, industrial, or household settingSodium carbonate
go.drugbank.com/drugs/DB09460ApprovedWithdrawnAs a strong base, sodium hydroxide neutralizes gastric acid thereby acting as an antacid. … Sodium Carbonate is the disodium salt of carbonic acid with alkalinizing property. When dissolved in water, sodium carbonate forms carbonic acid and sodium hydroxide.
Mixtures: GAVISCON® TABLETAS MASTICABLES SABOR A MENTADenosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigational; Both biosimilars also received marketing authorization in the EU in May 2024. … Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of
Products: CORORALebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigationalLebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab]. … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12
Eplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigationalThis approval was based on positive results demonstrated in the 35-week interim analysis from the Phase 3 NEURO-TTRansform study, where a consistent improvement in the Neuropathy Impairment Score +7 (mNIS … Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery.
Synonyms: Ion-ttr-lrx